Safety and feasibility of adjuvant chemotherapy with S-1 in Japanese breast cancer patients after primary systemic chemotherapy: a feasibility multicenter study

Safety and feasibility of adjuvant chemotherapy with S-1 in Japanese breast cancer patients after primary systemic chemotherapy: a feasibility multicenter study - A feasibility study using S-1 as adjuvant chemotherapy in breast cancer patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013469

Enrollment

Registered

2014-03-20

Start date

2007-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

(1) breast cancer with histological confirmation

Interventions

S-1

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) breast cancer with histological confirmation; (2) stage II or III breast cancer and previous standard anthracycline and/or taxane-based PSC, followed by curative surgery; (3) age 20-75 years; (4) Eastern Cooperative Oncology Group performance status 0,1; (5) adequate gastrointestinal function; (6) adequate organ function

Exclusion criteria

Exclusion criteria: Patients with serious complications, a history of drug hypersensitivity, brain metastases with any symptoms, active secondary cancer, or pregnant women

Design outcomes

Primary

Measure	Time frame
The primary endpoint was the percentage of the scheduled adjuvant chemotherapy completed using S-1 calculated by the Kaplan Meier method.	—

Countries

Japan

Contacts

Public ContactTakashi Shigekawa

Saitama Medical University International Medical Center Breast Oncology

t.shigekawa@gmail.com+81-42-984-4670

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026